tldrdailynews.com logo

Krystal Biotech Reports Positive Interim Results for CF Gene Therapy KB407

1 min read
Source: Krystal Biotech, Inc
TL;DR

Krystal Biotech announced positive interim results from its Phase 1 trial of KB407, a gene therapy for cystic fibrosis, confirming successful lung delivery and expression of wild-type CFTR protein across diverse patients, paving the way for a larger, repeat-dosing study expected to start in 2026.

Topics:businesshealthcare#clinical-trial#cystic-fibrosis#gene-therapy#healthcare#kb407#krystal-biotech
Share this article
  1. Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis  Krystal Biotech, Inc
  2. Krystal Biotech says it can deliver native protein to cystic fibrosis patients  Endpoints News
  3. Assessing Krystal Biotech (KRYS) Valuation As Investors Await CORAL-1 KB407 Interim Cystic Fibrosis Data  simplywall.st
  4. Krystal Biotech confirms CFTR delivery in CF patients with KB407 By Investing.com  Investing.com South Africa
  5. Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path  Yahoo Finance

Want the full story? Read the original reporting

Read on Krystal Biotech, Inc